BIIB.SW stock plunged -36.44% intraday on 09 Mar 2026, trading at CHF147.46 on the SIX after a sharp gap from the previous close of CHF232.00. The move makes Biogen Inc. (BIIB.SW) one of today’s top losers in the Swiss session and outpaced the Healthcare sector, which fell -3.54% on the day. Traders should note the unusually low reported volume (1.00 share) and the large price swing, which suggests a market-specific event or data anomaly worth watching in real time.
BIIB.SW stock: intraday sell-off and immediate drivers
Biogen Inc. (BIIB.SW) on the SIX showed a one-day decline of -36.44% to CHF147.46 on 09 Mar 2026.
The move follows a wider pullback in Healthcare but is far steeper than the sector daily fall of -3.54%, pointing to company-specific pressure rather than a pure sector decline. Investing.com US 500 components and related market lists show broader market context for the session.
Reported volume of 1.00 share and a relative volume of 10.00 indicate data oddities or a single large trade; traders should confirm tape prints and official SIX trade reports before acting.
Fundamentals and valuation snapshot for BIIB.SW stock
Biogen’s reported EPS is 6.80 and reported PE stands at 21.69 based on the latest quote, with a market cap near CHF21.60B. These measures reflect recent earnings power and the stock’s mid‑cap biotech valuation.
Key ratios show a price/book of 1.20 and price/sales of 2.70 (TTM). Cash per share is 14.94 and book value per share is 95.50, offering some balance-sheet support amid volatility.
Meyka AI rates BIIB.SW with a score out of 100: technicals and grade
Meyka AI rates BIIB.SW with a score out of 100: 71.37 (B+, BUY). This grade factors in S&P 500 comparison, sector and industry performance, financial growth, key metrics, and analyst consensus.
Technicals show RSI 40.02 and ADX 62.10, indicating a strong trending move. The 50/200 moving averages sit at CHF151.46, so the intraday price at CHF147.46 is trading below both short and long averages, increasing near-term downside risk.
Meyka AI’s forecast model projects future BIIB.SW stock levels
Meyka AI’s forecast model projects a 1‑year price of CHF189.88, a 3‑year price of CHF174.71, and a 5‑year price of CHF159.55 for BIIB.SW stock. Compared with the current price CHF147.46, the 1‑year projection implies an upside of 28.77%.
Forecasts are model‑based projections and not guarantees. Use them alongside earnings updates, pipeline news and regulatory developments, including Biogen’s next earnings on 06 May 2026.
Trading levels, price targets and risk factors for BIIB.SW stock
Near-term technical support is the year low CHF131.09 and the 50/200 MA at CHF151.46; immediate resistance is the prior close CHF232.00. A conservative near-term price target from current levels could be CHF160.00, with downside risk to CHF130.00 if the intraday move reflects fresh negative news.
Material risks include drug trial outcomes, regulatory actions for Alzheimer’s products, and volatility common in the Medical – Pharmaceuticals sector. BIIB.SW stock trading in CHF on SIX means currency and listing differences versus the US market can affect execution and quotes.
Actionable insights and what to watch next for BIIB.SW stock
Monitor official SIX trade reports and company releases for confirmation of the intraday move and any corporate disclosures.
Watch Biogen pipeline headlines (Alzheimer’s and MS assets), the upcoming 06 May 2026 earnings date, and sector flows into Healthcare. For a quick reference on order flow and levels, see BIIB.SW on Meyka: BIIB.SW on Meyka.
Final Thoughts
BIIB.SW stock’s -36.44% intraday drop to CHF147.46 on 09 Mar 2026 is a clear top‑loser signal for the SIX session. Fundamentals show an EPS of 6.80 and mixed valuation metrics, with a reported PE of 21.69 and price/book of 1.20. Meyka AI’s forecast model projects CHF189.88 in one year, implying an upside of 28.77% from the current price, while shorter‑term technicals point to immediate resistance at CHF151.46 and support near CHF131.09. Meyka AI rates BIIB.SW 71.37 (B+, BUY), reflecting a balance of pipeline upside and regulatory risk. Traders should verify the reported low volume and confirm any company or SIX notices before making trade decisions. Forecasts are model-based projections and not guarantees; use them with confirmed news and risk management.
FAQs
Why did BIIB.SW stock fall sharply intraday on 09 Mar 2026?
BIIB.SW stock fell -36.44% intraday on 09 Mar 2026. The drop outpaced the Healthcare sector, and the reported volume (1.00) suggests a possible data anomaly or single large trade. Confirm SIX trade reports and company releases for the cause.
What is Meyka AI’s outlook for BIIB.SW stock?
Meyka AI’s forecast model projects CHF189.88 in one year for BIIB.SW stock, implying 28.77% upside from CHF147.46. This is a model projection and not a guarantee; view it alongside fundamentals and regulatory news.
Which levels should traders watch for BIIB.SW stock after the drop?
Traders should watch support at the year low CHF131.09, the 50/200 moving average area at CHF151.46, and the prior close CHF232.00 as resistance. Confirm levels with live SIX order books.
Does BIIB.SW stock pay a dividend and what are its key ratios?
BIIB.SW stock shows no dividend yield (dividendPerShare TTM: none). Key ratios include EPS 6.80, reported PE 21.69, price/book 1.20, and cash per share 14.94.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)